- The patent reinforces Dewpoint’s leadership in discovering biomolecular condensate modulators with tremendous potential to treat diseases
- The new technology is the first to measure how a compound enters or breaks down a condensate to selectively target a single molecule to alter a disease
BOSTON, November 14, 2022 /PRNewswire/ — Dewpoint Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued patent “Methods of Characterizing Condensate-Associated Characteristics of Compounds and Uses of There” (US Patent No. 11493519) that covers novel technology for partitioning and identification of compounds that preferentially split into condensates of interest.
Biomolecular condensates are molecular assemblies that form through a process called phase separation, similar to the separation of oil from water. Various condensates are known to be important in modulating cellular processes and regulating many different functions of the cell, from controlling biochemical reaction rates to compartmentalizing proteins and nucleic acids into orchestrated transcription machines. Aberrant condensation function has also been implicated in human disease, including neurodegeneration and cancer. Condensation science holds promise, both for understanding the origin of disease and for discovering breakthrough treatments.
Little is known about the mechanisms that control the breakdown of compounds into condensates, how to design and test compounds to improve interactions with condensates, and how such information can be used to improve the treatment of disease.
Dewpoint’s granted patent is the first patented technology to measure how a compound enters or breaks down in a target condensate. This breakthrough technology will direct a compound to selectively target a single molecule in a condensate to alter disease.
“Dewpoint’s technology has far-reaching implications for drug discovery and maximizing drug efficacy,” he said Isaac Klein, MD, Ph.D., Chief Scientific Officer at Dewpoint. “It opens a new era of ‘condensate-directed’ drug discovery by allowing us to target a molecule to a condensate of interest. This can affect a drug’s activity by altering its local subcellular concentration and thus its potency. It’s a new one.” Medicinal chemistry mindset and lead optimization with the potential to improve drug efficacy.”
in the May 2022Dewpoint was granted a patent by the USPTO for a fundamental platform technology for a technology that identifies molecules that alter specific components of biomolecular condensates with high precision. Together, these patents claim technology critical to the discovery of new compounds that can be used to disrupt a condensate in specific ways to correct defective cellular functions and have tremendous therapeutic potential.
About dew point therapeutics
Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint believes that a variety of conditions have pathways that are regulated by condensates or arise from condensate dysfunction.
Dewpoint currently has more than 20 development programs in an ambitious pipeline with programs spanning oncology, neuromuscular, cardiopulmonary and virologic indications and collaborations with world-leading academic and pharmaceutical partners including Bayer, Merck and Pfizer. Dew point scientists work in BostonDresden and Frankfurt To translate condensation biology into breakthrough treatments for diseases previously thought untreatable.
Learn more at dewpointx.com and follow us Twitter and LinkedIn.
Scientists or investors interested in biomolecular condensates can also visit condensates.com for news and updates in the field.
VP, Head, Communications & PR
dew point therapeutics
+1 609-439-3997 | [email protected]
SVP, Corporate Development and Investor Relations
dew point therapeutics
SOURCE Dewpoint Therapeutics